Fenofibrate promotes PPARα-targeted recovery of the intestinal epithelial barrier at the host-microbe interface in dogs with diabetes mellitus
Abstract Diabetes mellitus (DM) is associated with a dysfunctional intestinal barrier and an increased risk for systemic infection and inflammation in people, though the pathogenic mechanisms leading to this are poorly understood. Using a canine model of DM, we showed that the peroxisomal proliferat...
Main Authors: | Katti R. Crakes, Jully Pires, Nina Quach, Riley E. Ellis-Reis, Rachel Greathouse, Kathyrnne A. Chittum, Jörg M. Steiner, Patricia Pesavento, Stanley L. Marks, Satya Dandekar, Chen Gilor |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Publishing Group
2021-06-01
|
Series: | Scientific Reports |
Online Access: | https://doi.org/10.1038/s41598-021-92966-7 |
Similar Items
-
Day‐to‐day variability of porcine lente, insulin glargine 300 U/mL and insulin degludec in diabetic dogs
by: Michelle Miller, et al.
Published: (2021-09-01) -
Efficacy of a micronized, nanocrystal fenofibrate formulation in treatment of hyperlipidemia in dogs
by: Matthew J. L. Munro, et al.
Published: (2021-07-01) -
Different skeletal effects of the peroxisome proliferator activated receptor (PPAR)α agonist fenofibrate and the PPARγ agonist pioglitazone
by: Nordsletten Lars, et al.
Published: (2009-03-01) -
PPAR-Alpha Agonist Fenofibrate Combined with Octreotide Acetate in the Treatment of Acute Hyperlipidemia Pancreatitis
by: Wen Bao, et al.
Published: (2021-01-01) -
The whole transcriptome effects of the PPARα agonist fenofibrate on livers of hepatocyte humanized mice
by: Montserrat A. de la Rosa Rodriguez, et al.
Published: (2018-06-01)